JPRN-jRCT2031220554招募中1 期
A Phase 1/1b Study of ASP2074 in Participants with Metastatic or Locally Advanced Solid Tumors
Guseva Maria0 个研究点目标入组 193 人开始时间: 2022年12月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 193
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Participant has locally-advanced (unresectable) or metastatic solid tumor malignancy (no limit to the number of prior treatment regimens) which is confirmed by available pathology records or current biopsy. For dose escalation, the participant must have colorectal, pancreatic, gastric cancer, esophageal or Gastroesophageal junction (GEJ) adenocarcinoma. For the tumor-specific expansion cohorts, the participant must have colorectal adenocarcinoma, esophageal or GEJ adenocarcinoma, or pancreatic adenocarcinoma.
- •2. Participant has at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •3. Participant has progressed or failed to tolerate after receiving all standard approved therapies or is no longer eligible for standard therapy (no limit to the number of prior treatment regimens).
- •4. Participant has an Eastern Cooperative Oncology Group (ECOG) Status of 0 or 1.
- •5. Participants who have received radiotherapy must have completed this therapy (including stereotactic radiosurgery) at least 2 weeks prior to study intervention administration.
- •6. Participant's adverse events (excluding alopecia) from prior therapy have improved to grade 1 or baseline for the participant (e.g., grade 2 hypothyroidism) within 14 days prior to the first dose of study intervention.
- •7. Participant has predicted life expectancy >= 12 weeks.
- •8. Participant must meet all of the criteria based on laboratory tests. In case of multiple laboratory data within this period, the most recent data should be used. If a participant has received a recent blood transfusion, the laboratory tests must be obtained >= 2 weeks after any blood transfusion.
- •9. Female participant is not pregnant confirmed by serum pregnancy test and medical evaluation by interview and at least 1 of the following conditions apply:
- •o Not a woman of childbearing potential (WOCBP)
- •o WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 90 days after final study intervention administration.
- •10. Female participant must agree not to breastfeed starting at screening and throughout the study period and for 90 days after final study intervention administration.
- •11. Female participant must not donate ova starting at first dose of study intervention and throughout the study period and for 90 days after final study intervention administration.
- •12. Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 90 days after final study intervention administration.
- •13. Male participant must not donate sperm during the treatment period and for 90 days after final study intervention administration.
- •14. Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 90 days after final study intervention administration.
- •15. Participant agrees not to participate in another interventional study while receiving study treatment in the present study.
排除标准
- •1. Participant has received other investigational agents or devices concurrently or within 21 days or 5 half-lives, whichever is shorter, prior to first dose of study intervention administration.
- •2. Participant has any condition which makes the participant unsuitable for study participation.
- •3. Participant has a known or suspected hypersensitivity to ASP2074 or any components of the formulation used.
- •4. Participants with squamous cell colorectal carcinoma; gastrointestinal stromal tumor and neuroendocrine carcinomas.
- •5. Participant weighs < 40 kg.
- •6. Participant requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to study intervention administration. Participants using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day prednisone), receiving a single dose of systemic corticosteroids, or receiving systemic corticosteroids as premedication for radiologic imaging contrast use is eligible.
- •7. Participant has symptomatic central nervous system (CNS) metastases or participant has evidence of unstable CNS metastases even if asymptomatic (e.g., progression on scans). Participants with previously treated CNS metastases are eligible, if they are clinically stable and have no evidence of CNS progression by imaging for at least 4 weeks prior to start of study treatment and are not requiring immunosuppressive doses of systemic steroids (> 30 mg per day of hydrocortisone or > 10 mg per day of prednisone or equivalent) for longer than 2 weeks.
- •8. Participant has an active autoimmune disease. Participants with type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy, or skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment are allowed.
- •9. Participant was discontinued from prior immunomodulatory therapy due to a grade >= 3 toxicity that was mechanistically related (e.g., immune related) to the agent.
- •10. Participant is known to have human immunodeficiency virus (HIV) infection. However, participants with HIV infection with CD4+ T-cell counts >= 350 cells/microL and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 6 months are eligible. NOTE: Screening for HIV infection should be conducted per local requirements.
- •11. Participant is known to have active hepatitis B (positive hepatitis B surface antigen (HBsAg)) or hepatitis C infection. NOTE: Screening for these infections should be conducted per local requirements.
- •o For participant who is negative for HBsAg, but hepatitis B core antibody (HBcAb) positive, a hepatitis B virus (HBV) DNA test will be performed and if positive the participant will be excluded.
- •o Participant with positive hepatitis C virus (HCV) serology, but negative HCV RNA test results are eligible.
- •o Participant treated for HCV with undetectable viral load results are eligible
- •12. Participant has received a live vaccine against infectious diseases within 28 days prior to initiation of study treatment.
- •13. Participant with a history of interstitial lung disease (ILD) or non-infectious pneumonitis, or currently has ILD/pneumonitis.
- •14. Participant has an infection requiring systemic therapy within 14 days prior to study drug treatment.
- •15. Participant has received a prior allogeneic bone marrow or solid organ transplant.
- •16. Participant is expected t
研究者
相似试验
招募中
1 期
A study of ASP2138 in adults with stomach cancer, gastroesophageal junction cancer, pancreatic cancerGastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Pancreatic AdenocarcinomaJPRN-jRCT2031210644Guseva Maria240
招募中
1 期
A study of ASP3082 in adults with previously treated solid tumorsJPRN-jRCT2031220738Fujii Hisaki356
进行中（未招募）
2 期
A Phase 2/3 study of S-217622JPRN-jRCT2031210350Gomez JuanCarlos2,694
进行中（未招募）
1 期
A study of ASP1570 taken by itself or with pembrolizumab in adults with solid tumorsAdvanced Solid TumorsMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104CTIS2023-505084-37-00Astellas Pharma Global Development Inc.330
招募中
1 期
A Study of ASP1570 taken by itself or with pembrolizumab in adults with solid tumorsocally advanced or metastatic solid tumorsJPRN-jRCT2031220527Sue Lee266